EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Early‐Onset Prostate Cancer: Epidemiology, Risk Factors, Biology, Clinical Features, Management, and Early Detection

Xingyu Xiong, Weizhen Zhu, Weichao Huang, Shiyu Zhang, Qi Deng, Jie Yang, Hang Xu, Qiang Wei, Lu Yang iD

MedComm · 2026-08 · 7 (8)

DOI: 10.1002/mco2.70858 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 22.07.2026. Verfasst von Xingyu Xiong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology Institute of Urology West China Hospital of Sichuan University Chengdu Sichuan Province China. Die Arbeit nennt 280 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The incidence of early‐onset prostate cancer (EOPC) is rising, and by 2045 a 24.5% increase in cases and a 50% rise in mortality are projected. Accumulating evidence indicates that EOPC represents a distinct disease entity, characterized by unique molecular features, risk factor profiles, and clinical behavior that differ from standard‐onset prostate cancer (SOPC). Nevertheless, research in this field remains nascent, and no consensus exists regarding the optimal management of EOPC. We synthesize current evidence on the epidemiology, molecular pathology, clinicopathological characteristics, survival, management, and early detection of EOPC. EOPC exhibits a distinctive molecular landscape, with TMPRSS2–ERG fusions occurring in 63–90% of cases as a hallmark alteration, whereas mutations in PTEN, SPOP, and CHD1 are significantly less frequent. Notably, the prevailing focus on hereditary EOPC has inadvertently led to the neglect of sporadic cases, which dominate clinical practice. Although localized EOPC confers no significant prognostic advantage over SOPC, high‐risk or metastatic early‐onset disease substantially elevates prostate‐cancer‐specific mortality. By critically appraising the existing evidence, we identify key knowledge gaps, such as the understudied sporadic EOPC subgroup and the lack of dedicated clinical trials, and propose future research directions to inform early detection and optimize therapeutic strategies for this unique patient population.

Schlagwörter

Stichwörter der Autor:innen

early detectionearly‐onset prostate cancermanagementrisk factorssurvival

Autor:innen und Institutionen

  • Department of Urology Institute of Urology West China Hospital of Sichuan University Chengdu Sichuan Province China.

ORCID-Profile: Lu Yang

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

Xiong, X., Zhu, W., Huang, W., Zhang, S., Deng, Q., Yang, J., Xu, H., Wei, Q., & Yang, L. (2026). Early‐Onset Prostate Cancer: Epidemiology, Risk Factors, Biology, Clinical Features, Management, and Early Detection. MedComm, 7(8). https://doi.org/10.1002/mco2.70858

Vancouver

Xiong X, Zhu W, Huang W, Zhang S, Deng Q, Yang J, et al. Early‐Onset Prostate Cancer: Epidemiology, Risk Factors, Biology, Clinical Features, Management, and Early Detection. MedComm. 2026;7(8). doi:10.1002/mco2.70858

BibTeX
@article{Xiong2026,
  author = {Xiong, Xingyu and Zhu, Weizhen and Huang, Weichao and Zhang, Shiyu and Deng, Qi and Yang, Jie and Xu, Hang and Wei, Qiang and Yang, Lu},
  title = {Early‐Onset Prostate Cancer: Epidemiology, Risk Factors, Biology, Clinical Features, Management, and Early Detection},
  journal = {MedComm},
  year = {2026},
  volume = {7},
  number = {8},
  doi = {10.1002/mco2.70858}
}
Kostenlos starten →